Ananda Pharma PLC - Redemption of Unsecured CLNs and Director Dealing

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

03 December 2025

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

Redemption of Unsecured Convertible Loan Notes and Director Dealing

Ananda Pharma plc (AQSE: ANA, OTC: ANANF),  a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, announces the automatic redemption of the 600,000 of £1 each denomination unsecured, interest bearing convertible loan notes (the "CLNs") issued by the Company in September 2023 (https://investors.anandapharma.co.uk/announcements/5456547). The Company has issued 150,000,000 Ordinary Shares at a deemed conversion price of £0.004 per Ordinary Share. The accrued interest of £233,843.02 will remain as unsecured debt. As Charles Morgan was the holder of 300,000 CLNs, he will become interested in a further 75,000,000 Ordinary Shares.

Holding in Company

Following the issue of the 75,000,000 Ordinary Shares pursuant to the Convertible loan note redemption, Mr Charles Morgan will hold 2,503,875,896 Ordinary Shares representing 56.28 per cent. of the share capital as enlarged by the issue of the Ordinary Shares to satisfy the CLN redemption, as detailed above.

The Company announced on 24 November 2025 that it would be seeking approval from its shareholders to delist from the Aquis exchange. If shareholders approve the delisting at the general meeting to be held on 12 December 2025, then the delisting will be effective at 8.00 a.m. on 22 December 2025.

Admission and Total Voting Rights

An application has been made to the Aquis Stock Exchange for 150,000,000 Ordinary Shares to be admitted to trading on AQSE with effect from 8 a.m. on or around 9^th December 2025 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Following Admission, the Company will have 4,449,146,581 Ordinary Shares in issue, each share carrying the right to one vote. This figure of 4, 449,146,581 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh.

For more information, please visit our website:

To stay up to date with Ananda's news please follow our social media channels:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

-Ends-

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.  

https://investors.anandapharma.co.uk/link/r8KmGe